Skip to main content
MRSH
NYSE Finance

Q1 Earnings Hit by $425M Greensill Litigation Charge Despite Revenue Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Insurance Stocks · Financial
Sentiment info
Negative
Importance info
8
Price
$177
Mkt Cap
$84.673B
52W Low
$164.89
52W High
$239.34
52W Position info
7.3% above low
Off High info
26% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

MRSH is trading near its 52-week low of $164.89 (7.3% above the low).

Summary

Marsh & McLennan reported Q1 2026 revenue growth, but a $425 million charge from the Greensill litigation caused a 12% drop in operating income and a 15% decline in diluted EPS.


Key Events · Earnings and Guidance · MRSH

  • Q1 2026 Financial Performance

    Consolidated revenue increased 8% (4% on an underlying basis) to $7.6 billion. However, operating income decreased 12% to $1.8 billion, and diluted EPS fell 15% to $2.36, compared to the prior year period.

  • Significant Greensill Litigation Charge

    The company recorded a $425 million gross liability and legal expenses in Q1 2026 related to the ongoing Greensill litigation in Australia, which was the primary driver for the decline in profitability.

  • Share Repurchase Activity

    Marsh & McLennan repurchased $750 million of its common stock in Q1 2026, with approximately $4.9 billion remaining under the existing authorization, continuing its capital return program.

  • Debt Management

    The company issued $600 million in 4.950% senior notes due 2036 and repaid $600 million in 3.750% senior notes at maturity, actively managing its debt portfolio.


Analysis · MRSH · Finance

Marsh & McLennan's first-quarter results show solid underlying revenue growth, but profitability was significantly impacted by a substantial $425 million charge related to the Greensill litigation. This legal liability led to a double-digit decline in operating income and diluted EPS, overshadowing the positive top-line performance. Investors should monitor the ongoing litigation's future impact and the progress of the 'Thrive' restructuring program, which is incurring costs while aiming for efficiency gains.

At the time of this filing, MRSH was trading at $177.00 on NYSE in the Finance sector, with a market capitalization of approximately $84.7B. The 52-week trading range was $164.89 to $239.34. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MRSH - Latest Insights

MRSH
Jul 21, 2026, 8:13 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $182.00
Real-time Price: $192.20 info
Change: +$10.20 (+6%) info
Market Cap: $91.715B info
MRSH
Jul 21, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $182.00
Real-time Price: $192.20 info
Change: +$10.20 (+6%) info
Market Cap: $91.715B info
MRSH
Jul 08, 2026, 12:00 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $179.11
Real-time Price: $192.20 info
Change: +$13.09 (+7%) info
Market Cap: $91.715B info
MRSH
Jun 04, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $157.32
Real-time Price: $192.20 info
Change: +$34.88 (+22%) info
Market Cap: $91.715B info
MRSH
Jun 03, 2026, 5:32 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $157.32
Real-time Price: $192.20 info
Change: +$34.88 (+22%) info
Market Cap: $91.715B info